Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for CareDx Inc. (CDNA:NASDAQ), powered by AI.
CareDx Inc. is currently trading at $22.97. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for CareDx Inc. on Alpha Lenz.
CareDx Inc.'s P/E ratio is -57.3.
“CareDx Inc. trades at a P/E of -57.3 (undervalued) with modest ROE of -6.3%.”
Ask for details →CareDx Inc. is a precision medicine company that specializes in transplant care. The firm's primary mission is to improve the outcomes of organ transplant patients through innovative diagnostic solutions and services. CareDx provides a variety of products that monitor the health of organ transplants, notably its AlloSure and AlloMap tests, which use genomic technology to assess the probability of organ rejection in kidney and heart transplant recipients. Operating at the intersection of biotechnology and healthcare, CareDx Inc. plays a crucial role in the life sciences sector, aiming to enhance patient care by offering non-invasive diagnostic options that provide timely and critical information to healthcare providers. Their products are integrated into transplant centers worldwide, highlighting the company's vital role in the healthcare ecosystem. By facilitating proactive and personalized patient management, CareDx helps reduce healthcare costs and improve patient longevity and quality of life. The company's technologies are also vital in the development of precision medicine, contributing significantly to advancements in biotechnology and the customization of treatment plans for patients globally.
“CareDx Inc. trades at a P/E of -57.3 (undervalued) with modest ROE of -6.3%.”
Ask for details →CareDx Inc. (ticker: CDNA) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 644 employees. Market cap is $1.2B.
The current price is $22.97 with a P/E ratio of -57.32x and P/B of 4.04x.
ROE is -6.27% and operating margin is -6.60%. Annual revenue is $380M.